Teladoc price target lowered to $7 from $8 at Goldman Sachs

Goldman Sachs analyst David Roman lowered the firm’s price target on Teladoc (TDOC) to $7 from $8 and keeps a Buy rating on the shares after its Q4 results. Growth in the quarter was led by Integrated Care, which came in towards the high end of guidance, and in the BetterHelp segment, the company continued to face significant pressures in the U.S. market, partly offset by strength in International, the analyst tells investors in a research note.